Yeşim COŞKUNCanan YILDIRIM2024-05-252024-05-2520212630-572010.14744/hnhj.2020.04864https://doi.org/10.14744/hnhj.2020.04864https://search.trdizin.gov.tr/tr/yayin/detay/489231/the-efficacy-of-lacosamide-in-children-with-drug-resistant-focal-epilepsyhttps://hdl.handle.net/20.500.14517/1936Introduction: This study aimed to assess the efficacy, tolerability and adverse effects of Lacosamide (LCM) in children with refractory focal epilepsy. Methods: Children aged younger than 16 years with drug-resistant focal epilepsy were enrolled. The medical records and seizure diaries that were evaluated every three months were reviewed. Response to LCM was defined as ≥50% reduction in seizure frequency. Results: Twenty-five children with drug-resistant focal epilepsy received LCM as add-on therapy. The mean duration of epi- lepsy was 5.2 years and the mean age at LCM initiation was 8 years. The rate of response to LCM treatment in the 3th, 6th and 9th months were 44%, 64%, 76%, respectively. At the end of 12 months, the response rate was 84% and 16% of the patients were seizure free. Four patients had adverse effects; three patients were discontinued LCM and one improved after decreas- ing the dose of the drug. Discussion and Conclusion: LCM is an effective add-on antiepileptic drug for children with refractory focal epilepsy. It dimin- ishes the frequency of seizures over time. It is well tolerated and a promising option in these patients.eninfo:eu-repo/semantics/openAccessArticle61152574892310